eMedicine Specialties > Pediatrics: General Medicine > Dermatology

Atopic Dermatitis

Author: Caroline C Spagnola, MD, Consulting Staff, Department of Allergy and Immunology, Kaiser Permanente Bellflower
Contributor Information and Disclosures

Updated: Sep 30, 2009

Introduction

Background

Atopic dermatitis (AD) is a chronically relapsing skin disorder with an immunologic basis. The clinical presentation varies from mild to severe. In the worst cases, atopic dermatitis may interfere with normal growth and development. Treatment consists of adequate skin hydration, avoidance of allergenic precipitants, topical anti-inflammatory medications, systemic antihistamines, and antibiotic coverage of secondary infections.

Although often used interchangeably, the terms eczema and atopic dermatitis are not equivalent. Eczema is a reaction pattern with various causes, the most common pediatric cause is atopic dermatitis. Other causes of eczematous dermatitis include allergic contact dermatitis, irritant contact dermatitis, seborrheic dermatitis, nummular eczema, dyshidrotic eczema, asteatotic eczema, and lichen simplex chronicus. Eczematous reactions can be classified as acute, subacute, or chronic, depending on historical and physical characteristics.

Typical atopic dermatitis on the face of an infan...

Typical atopic dermatitis on the face of an infant.

Typical atopic dermatitis on the face of an infan...

Typical atopic dermatitis on the face of an infant.


Flexural involvement in childhood atopic dermatit...

Flexural involvement in childhood atopic dermatitis.

Flexural involvement in childhood atopic dermatit...

Flexural involvement in childhood atopic dermatitis.


Pathophysiology

Clinically unaffected skin in patients with atopic dermatitis has increased numbers of T-helper type 2 (Th2) cells compared with skin in patients without atopic dermatitis. Increased levels of interleukin (IL)-4 and IL-13 (Th2 cytokines) are seen in acute atopic dermatitis skin lesions, whereas chronic atopic dermatitis lesions show increased expression of IL-5 (Th2 cytokine) and IL-12 and interferon (IFN)-γ (Th1 cytokines). Chronic atopic dermatitis lesions also exhibit greater eosinophil infiltration compared with skin in patients without atopic dermatitis. 

IL-4 enhances differentiation of T-helper cells along the Th2 pathway, and IL-13 acts as a chemoattractant for Th2 cells to infiltrate atopic dermatitis lesions. IL-13 may also directly induce IL-5 expression and eosinophil infiltration, thereby facilitating the transition from acute lesions into chronic lesions.1

In addition, patients with atopic dermatitis appear to have significantly decreased levels of skin barrier molecules compared with normal controls. Ceramide lipids in the stratum corneum, which are responsible for water retention and permeability functions, and skin barrier proteins such as filaggrin are expressed at significantly lower levels in the skin of patients with atopic dermatitis compared with the skin of patients without atopic dermatitis.1,2

Frequency

United States

Atopic dermatitis occurs in approximately 10-20% of children and 2% of adults.1 Children with concurrent asthma or hayfever have a 30-50% incidence of developing atopic dermatitis.

International

Prevalence rates for atopic dermatitis in children over a 1-year period ranged from around 2% in Iran and China to about 20% in Australasia, England, and Scandinavia.3 Interestingly, populations that migrate from areas of low prevalence to areas of higher prevalence have shown an increased incidence of atopic dermatitis, bolstering the idea of strong environmental influences in the development of atopic dermatitis.

Race

No clear racial predilections have been identified.

Sex

Males and females are affected with equal incidence and severity.

Age

Atopic dermatitis may occur in people of any age but often starts in infants aged 2-6 months. Ninety percent of patients with atopic dermatitis experience the onset of disease prior to age 5 years.4 Seventy-five percent of individuals experience marked improvement in the severity of their atopic dermatitis by age 14 years; however, the remaining 25% continue to have significant relapses during their adult life. A recent study concluded that the prevalence of atopic dermatitis in children younger than 2 years was 18.6%.5

Clinical

History

Diagnostic criteria for atopic dermatitis (AD) have been proposed by Hanifin and Rajka (1980) and largely adopted by the American Academy of Allergy, Asthma, and Immunology.6 Appropriate cases must have at least 3 major characteristics and at least 3 minor characteristics.

  • Major characteristics include the following:
    • Pruritus
    • Typical morphology and distribution (ie, flexural lichenification and linearity in adults, facial and extensor involvement in infants and young children)
    • Chronic or chronically relapsing dermatitis
    • Personal or family history of atopy (eg, asthma, allergic rhinoconjunctivitis, atopic dermatitis)
  • Minor characteristics are as follows:
    • Xerosis (dry skin)
    • Ichthyosis, palmar hyperlinearity, keratosis pilaris
    • Hand dermatitis, foot dermatitis
    • Cheilitis
    • Nipple eczema
    • Susceptibility to cutaneous infection (eg, with Staphylococcus aureus, herpes simplex virus [HSV], other viruses, warts, molluscum, dermatophytes)
    • Erythroderma
    • Perifollicular accentuation
    • Pityriasis alba
    • Early age of onset
    • Impaired cell-mediated immunity
    • Recurrent conjunctivitis
    • Orbital darkening
    • Infraorbital fold (eg, Dennie pleat, Morgan fold)
    • Anterior neck folds
    • Keratoconus
    • Anterior subcapsular cataracts
    • Sensitivity to emotional factors
    • Food intolerance
    • Pruritus with sweating
    • Intolerance of wool
    • White dermographism
    • Immediate type I skin test response
    • Elevated total serum immunoglobulin E (IgE)
    • Peripheral blood eosinophilia

Most children with atopic dermatitis relate a history notable for intense pruritus and dry skin. The quality of the pruritus is referred to as a spreading itch. Affected children often have a lowered itch threshold, resulting in increased levels of cutaneous reactivity in response to stimuli. Patients may succumb to a vicious itch-scratch-itch cycle, in which pruritus stimulates a bout of scratching. This, in turn, increases skin inflammation and triggers a greater sensation of itching, thus exacerbating flares.

Altered cell-mediated immunity has been noted in patients with atopic dermatitis. This is clinically observed as a history of repeated unusual cutaneous infections (eg, eczema herpeticum, warts, molluscum, dermatophytes).

Physical

  • Three classes of skin lesions are recognized.
    • Acute - Intensely pruritic erythematous papules and vesicles overlying erythematous skin; frequently associated with extensive excoriations and erosions accompanied by serous exudates
    • Subacute - Erythema, excoriation, and scaling
    • Chronic - Thickened plaques of skin, accentuated skin markings (lichenification), fibrotic papules (prurigo nodularis); possible coexistence of all 3 types of lesions in chronic atopic dermatitis
  • Typical locations of lesions by age
    • Nonmobile infant - Face and scalp
    • Crawling infant - Extensor surfaces of extremities, trunk, face, and neck
    • Older child and adolescent - Wrists, ankles, antecubital fossae, popliteal fossae, and neck
    • Adult - May be limited to hand and foot eczema
  • Associated findings in atopic dermatitis include keratosis pilaris; accentuated palmar creases; lichenification; atopic pleats; allergic shiners; transverse nasal crease; pallor around the nose, mouth, and ears; white dermographism; cataracts; and keratoconus.
    • Keratosis pilaris, or plucked-chicken skin, consists of large cornified plugs in the upper part of hair follicles and produces a stippled appearance of the skin on the outer aspects of the arms and legs and on the buttocks and trunk.
    • Hyperlinear palms are usually present at birth and persist throughout life. These consist of an increased number of fine lines and accentuated markings on the palms.
    • Lichenification of the wrists, ankles, popliteal fossae, or antecubital fossae is characteristic of chronic atopic dermatitis. It is observed as thickened, leathery, hyperpigmented patches of skin with a deepening of normal skin creases.
    • Atopic pleats (also referred to as Morgan-Dennie folds, Morgan folds, Dennie pleats, or mongolian lines) are skin folds observed just below the lower lid of both eyes and are retained throughout life.
    • Allergic shiners are violet-gray infraorbital discolorations caused by underlying vascular stasis. Increased pressure on nasal and paranasal venous plexuses causes edema in these areas, leading to development of atopic pleats and allergic shiners.
    • A prominent transverse nasal crease is a common sign of concurrent allergic rhinitis and, along with allergic shiners and atopic pleats, may be a clue to the diagnosis of an atopic diathesis.
    • Dermographism is a normal reaction in 5% of the population. After a firm pointed instrument is stroked against the skin, the path of the instrument is observed as a red line followed by an erythematous flare that ultimately develops into a wheal. This response occurs within 3 minutes of the insult. White dermographism is a paradoxical reaction wherein the initial red line is replaced within 10 seconds by a white line and an absence of a wheal. This reaction can be observed in atopic dermatitis and allergic contact dermatitis.
    • Atopic cataracts affect 4-12% of patients with AD and occur much earlier in life than senile cataracts. They typically are bilateral, central, and shield-shaped, and they mature rapidly. Because patients generally are asymptomatic, diagnosis is usually made by slit lamp examination. Incidence of cataracts in atopic patients appears to be unrelated to the use of topical steroids.
    • Keratoconus is an elongation of the corneal surface that is thought to be caused by long-term eye rubbing and may be a degenerative change in the cornea. Keratoconus affects approximately 1% of children with atopic dermatitis and can generally be alleviated with the use of contact lenses.

Causes

The etiology of atopic dermatitis appears to be linked both to genetic causes and to environmental agents.

  • The prevalence of atopic dermatitis in children with one affected parent is 60% and rises to nearly 80% for children of two affected parents. Additionally, nearly 40% of patients with newly diagnosed cases report a positive family history for atopic dermatitis in at least one first-degree relative. Much higher concordance rates for atopic dermatitis are observed in monozygotic twins (77%) than in dizygotic twins (15%).1
  • Recent evidence has demonstrated a strong genetic predisposition towards the development of atopic dermatitis in patients with loss-of-function mutations in the gene that encodes the epidermal structural protein filaggrin (FLG). Filaggrin deficiency causes a significant defect in the normal epidermal barrier that allows for enhanced allergen absorption through the skin, resulting in a higher incidence of dermatitis. FLG gene mutations have been associated with a more severe atopic dermatitis phenotype, earlier onset of atopic dermatitis, increased levels of systemic allergen sensitivity, and a higher proportion of patients with atopic dermatitis who eventually develop asthma.7
  • Environmental allergens repeatedly have been shown to trigger exacerbations of atopic dermatitis in susceptible individuals. Contact irritants, climate, sweating, aeroallergens, microbial organisms, and stress/psyche commonly trigger exacerbations.
    • Contact irritants (eg, soaps, solvents, wool clothing, mechanical irritants, detergents, preservatives, perfumes) compromise the integument, creating inflammation, irritation, and a portal of entry for further environmental insult. These surface irritants, along with the macerative effects of sweating and the drying effects of low humidity, lower the pruritic threshold. A vicious cycle of itching and scratching ensues, in which added cutaneous damage caused by scratching further lowers the pruritic threshold and subsequently causes increased itching.
    • Aeroallergens (eg, house dust mite, molds, pollen, dander) induce peripheral eosinophilia and elevate serum IgE levels. These early effects lead to increased histamine release from IgE-activated mast cells and elevated activity of the T-helper cell–mediated immune system. The increased release of vascular mediators (eg, bradykinin, histamine, slow-reacting substance of anaphylaxis [SRS-A]) induces vasodilation, edema, and urticaria, which in turn stimulate pruritus and inflammatory cutaneous changes.
    • Microbial agents (eg, S aureus, Pityrosporum yeasts, Candida organisms, Trichophyton dermatophytes) act in 2 different ways to promote the flares of atopic dermatitis. The microorganisms directly invade the skin, creating local injury and inflammation, and they induce a systemic allergic response to specific antigens, causing a rise in serum IgE and enhanced activity of the immune system.
      • Nearly all patients with atopic dermatitis are colonized by S aureus on lesional skin. More than half of patients with atopic dermatitis are colonized by S aureus strains capable of producing superantigens. These patients can develop superantigen-specific IgE antibodies that activate inflammatory cells in the skin. Staphylococcal enterotoxin B is a superantigen known to upregulate interleukin (IL)-31 expression in skin. IL-31 has been shown to induce pruritus and skin lesions resembling atopic dermatitis in mice.1
      • Specific IgE levels to Malassezia furfur have been correlated with atopic dermatitis severity in a subgroup of patients. These Malassezia -specific IgE antibodies have been shown to crossreact with autoantigens in atopic dermatitis skin.1
    • Food allergy is implicated in one-third to one-half of children with atopic dermatitis. Food allergens may be the initial trigger for IgE autoreactivity to epithelial autoantigens in young children with atopic dermatitis.1 The most common food allergens in children include egg, soy, milk, wheat, fish, shellfish, and peanut, which together account for 90% of food-induced cases of atopic dermatitis in double-blind, placebo-controlled food challenges. Fortunately, many clinically significant food allergies self-resolve within the first 5 years of life, eliminating the need for long-term restrictive diets.
    • Stress may trigger atopic dermatitis at the sites of activated cutaneous nerve endings, possibly by the actions of substance P, vasoactive intestinal peptide (VIP), or via the adenyl cyclase–cyclic adenosine monophosphate (cAMP) system.

More on Atopic Dermatitis

Overview: Atopic Dermatitis
Differential Diagnoses & Workup: Atopic Dermatitis
Treatment & Medication: Atopic Dermatitis
Follow-up: Atopic Dermatitis
Multimedia: Atopic Dermatitis
References

References

  1. Ong PY, Leung DY. Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep. Sep 2006;6(5):384-9. [Medline].

  2. Oranje AP, Devillers AC, Kunz B, et al. Treatment of patients with atopic dermatitis using wet-wrap dressings with diluted steroids and/or emollients. An expert panel's opinion and review of the literature. J Eur Acad Dermatol Venereol. Nov 2006;20(10):1277-86. [Medline].

  3. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR,. Is eczema really on the increase worldwide?. J Allergy Clin Immunol. Apr 2008;121(4):947-54.e15. [Medline].

  4. Ong PY, Boguniewicz M. Atopic dermatitis. Prim Care. Mar 2008;35(1):105-17, vii. [Medline].

  5. [Best Evidence] Kvenshagen B, Jacobsen M, Halvorsen R. Atopic dermatitis in premature and term children. Arch Dis Child. Mar 2009;94(3):202-5. [Medline].

  6. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venreol. 1980;92:44-7.

  7. Leung DY. Our evolving understanding of the functional role of filaggrin in atopic dermatitis. J Allergy Clin Immunol. Sep 2009;124(3):494-5. [Medline].

  8. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. Aug 2002;47(2):198-208. [Medline].

  9. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol. Dec 2007;7(6):542-46. [Medline].

  10. Greer FR, Sicherer SH, Burks AW. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics. Jan 2008;121(1):183-91. [Medline].

  11. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. Jan 2008;121(1):122-8. [Medline].

  12. Bukutu C, Deol J, Shamseer L, Vohra S. Complementary, holistic, and integrative medicine: atopic dermatitis. Pediatr Rev. Dec 2007;28(12):e87-94. [Medline].

  13. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol. Jan 2008;121(1):116-121.e11. [Medline].

  14. [Guideline] Patel TS, Greer SC, Skinner RB Jr. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. Am J Clin Dermatol. 2007;8(4):189-94. [Medline].

  15. Ring J, Mohrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008;31(3):185-98. [Medline].

  16. Boguniewicz M. Topical treatment of atopic dermatitis. Immunol Allergy Clin North Am. Nov 2004;24(4):631-44, vi-vii. [Medline].

  17. Bisgaard H, Halkjaer LB, Hinge R, et al. Risk analysis of early childhood eczema. J Allergy Clin Immunol. Jun 2009;123(6):1355-60.e5. [Medline].

  18. Beltrani VS. Atopic dermatitis: An update. J Allergy Clin Immunol. Sep 1999;104(3 Pt 2):S85-6. [Medline].

  19. Boguniewicz M. Advances in the understanding and treatment of atopic dermatitis. Curr Opin Pediatr. Dec 1997;9(6):577-81. [Medline].

  20. Boguniewicz M. Topical treatment of atopic dermatitis. Immunol Allergy Clin North Am. Nov 2004;4:631-44. [Medline].

  21. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol. Jan 2001;44(1 Suppl):S65-72. [Medline].

  22. [Guideline] Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for nevi I (nevocellular nevi and seborrheic keratoses). Committee on Guidelines of Care. Task Force on Nevocellular Nevi. J Am Acad Dermatol. Apr 1992;26(4):629-31. [Medline].

  23. Eichenfield LF, Lucky AW, Boguniewicz M. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. Apr 2002;46(4):495-504. [Medline].

  24. Gdalevich M, Mimouni D, David M, Mimouni M. Breast-feeding and the onset of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective studies. J Am Acad Dermatol. Oct 2001;45(4):520-527. [Medline].

  25. Grundmann-Kollmann M, Kaufmann R, Zollner TM. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol. Aug 2001;145(2):351-2. [Medline].

  26. Gutman ab, Kligman am, Sciacca j, James WD. Soak and smear: A standard technique revisited. Arch Dermatol. 2005;141:1556-9. [Medline].

  27. Halbert AR, Weston WL, Morelli JG. Atopic dermatitis: is it an allergic disease?. J Am Acad Dermatol. Dec 1995;33(6):1008-18. [Medline].

  28. Hamzavi I, Lui H. Using light in dermatology: an update on lasers, ultraviolet phototherapy, and photodynamic therapy. Dermatol Clin. Apr 2005;23(2):199-207. [Medline].

  29. Hanifin JM, Tofte SJ. Update on therapy of atopic dermatitis. J Allergy Clin Immunol. Sep 1999;104(3 Pt 2):S123-5. [Medline].

  30. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. Feb 2003;142(2):155-62. [Medline].

  31. Hurwitz S. Eczematous eruptions in childhood. In: Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence. 2nd ed. Philadelphia, PA: WB Saunders Co; 1993:45-60.

  32. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. Jan 2001;44(1 Suppl):S58-64. [Medline].

  33. Knoell KA, Greer KE. Atopic dermatitis. Pediatr Rev. Feb 1999;20(2):46-51; quiz 52. [Medline].

  34. Krutmann J, Diepgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol. Apr 1998;38(4):589-93. [Medline].

  35. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol. Sep 2004;93(3 Suppl 2):S1-21. [Medline].

  36. Rasmussen JE. Advances in nondietary management of children with atopic dermatitis. Pediatr Dermatol. Sep 1989;6(3):210-5. [Medline].

  37. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. Jun 23 2001;357(9273):2012-6. [Medline].

  38. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol. Feb 2003;111(2):389-95. [Medline].

  39. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. Jun 6 1998;351(9117):1715-21. [Medline].

  40. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. Sep 18 1997;337(12):816-21. [Medline].

  41. Sherertz EF. Atopic Dermatitis: Pathogenesis and Treatment. Medscape from WebMD. Available at http://www.medscape.com/viewarticle/427351. Accessed November 14, 2008.

  42. Uehara M, Sugiura H, Sakurai K. A trial of oolong tea in the management of recalcitrant atopic dermatitis. Arch Dermatol. Jan 2001;137(1):42-3. [Medline].

  43. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. Jul 2002;110(1 Pt 1):e2. [Medline].

Further Reading

Keywords

atopic dermatitis, AD, eczema, immunologic skin disorder, hyperactive T helper cell 2, hyperactive Th2, elevated serum immunoglobulin E, elevated serum IgE, deficient levels of omega-6 fatty acids, disorder of fatty acid metabolism, pruritus, dermatitis, flexural lichenification and linearity in adults, facial and extensor involvement in infants and young children, atopy, dry skin, xerosis, skin inflammation, inflamed skin, asthma, hayfever, Staphylococcus aureus, herpes simplex virus, HSV, warts, molluscum, dermatophytes, food intolerance, keratosis pilaris, accentuated palmar creases, lichenification, atopic pleats, allergic shiners, transverse nasal crease

Contributor Information and Disclosures

Author

Caroline C Spagnola, MD, Consulting Staff, Department of Allergy and Immunology, Kaiser Permanente Bellflower
Caroline C Spagnola, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, and American College of Allergy, Asthma and Immunology
Disclosure: Nothing to disclose.

Medical Editor

Kevin P Connelly, DO, Clinical Assistant Professor, Department of Pediatrics, Division of General Pediatrics and Emergency Care, Virginia Commonwealth University; Medical Director, Paws for Health Pet Visitation Program of the Richmond SPCA; Pediatric Emergency Physician, Emergency Consultants Inc, Chippenham Medical Center
Kevin P Connelly, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.

CME Editor

Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences
Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.